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Keratitis is an ocular disease characterized by inflammation of the cornea. If not treated 
quickly and efficiently, keratitis can lead to ocular morbidity. It is categorized, based on causal 
agent, into non-infectious and infectious keratitis. Non-infectious keratitis is commonly due to 
ocular injury or prolonged use of contact lenses and can lead to opportunistic infection; these 
infectious agents consist of HSV-1, Staphylococcus, Candida, and Acanthamoeba, among others. 
Treatment of infectious/microbial keratitis differs depending on the pathogen and each patient 
requires unique care and treatment. Topical administration of drugs, via eyedrops, is the most 
common form of initial treatment for keratitis. However, physiological barriers within the eye lead 
to poor bioavailability of drug from eyedrops, and frequent administration is needed to overcome 
this challenge. Since conventional treatment is not ideal, it is important to develop novel drugs and 
delivery methods that are more appropriate for treating ocular conditions and protect the corneal 
epithelium. Novel pharmaceutical approaches, such as drug-loaded contact lenses, in situ gel 
formulations, and nanoparticle-carriers are some of the most promising novel drug delivery 
methods currently being investigated. They are being used to deliver common antimicrobial agents 
such as nucleosides, fluroquinolones, and steroids, but with greater ocular bioavailability. A novel 
non-pharmaceutical approach, corneal crosslinking, has also been developed to treat keratitis. This 
review will discuss these current treatment options and conventional challenges regarding keratitis, 
with an emphasis on keratitis due to microbial pathogens.  
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1.0 Introduction 
Keratitis is an ocular condition characterized by inflammation of the cornea. The cornea is 
the transparent covering of the eye that serves as a physical barrier and is  responsible for 
refraction of light onto the retina. It is composed of five different layers listed in Figure 1 
(Cleveland 2018), with the corneal epithelium as the outermost layer that interacts with the tear 
film to wash and protect the eye.  The epithelium itself is composed of 5-7 layers of nonkeratinized 
cells and is about 50 μm in thickness (Voss, Nguyen et al. 2021). Infiltration of the corneal 
epithelium by inflammatory cells can lead to ocular morbidity, especially with deeper corneal 
infiltrates.  
Inflammatory cell migration and proliferation can be in response to non-infectious factors, 
such as ocular trauma, improper contact lens use, or autoimmune diseases, as well as pathogens 
like various viruses, bacteria, fungi, or amoeba. These causes may be systemic or localized to the 
corneal epithelium; in the case of the former, systemic antigens and viruses can cause corneal 
damage by traveling through the trigeminal ganglia and ophthalmic nerves to the eye, facilitating 
corneal inflammation (Koganti, Yadavalli et al. 2021). Ocular trauma can cause disruption of the 
corneal epithelium and also compromise its protective function, facilitating local opportunistic 
infection. Local infection begins at the epithelium, recruiting leukocytes and macrophages; these 
inflammatory cells, in addition to the pathogen itself, release hydrolases and proteases that 
contribute to the condition (Singh, Gupta et al. 2021). Further progression can result in epithelial 
ulceration and stromal infiltration, damaging the structural integrity of the cornea. 
Although keratitis can develop in any individual, it is predominantly found in contact lens 
wearers; prolonged/improper contact lens use is the primary risk factor for developing keratitis 
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and it is estimated that almost 17% of adults wear contact lenses daily in the United States 
(Scruggs, Quist et al. 2019). Furthermore, it is estimated that $175 million is spent annually on 
keratitis treatment, with nearly one million doctor’s office or emergency room visits throughout 
the US (Collier, Gronostaj et al. 2014).  
Typical symptoms of keratitis include eye pain/burning, redness, and blurred vision. In 
severe cases of keratitis, or if infection progresses without adequate treatment, partial or total 
vision loss can occur. Therefore, it is important to develop efficacious treatments that can prevent 
progression of the condition in an individual. Although the eye is accessible and immunologically 
isolated, various physiological barriers, including the corneal epithelium itself, pose a challenge 
for drug delivery. Conventional treatment involves the use of drug-loaded eyedrops administered 
multiple times throughout the day; however, as will be discussed in this review, topical treatment 
is not ideal. As a result, various novel drugs and delivery methods are currently being investigated, 
both in animal models as well as human patients; these novel approaches for treatment of keratitis 





Figure 1. Anatomy of the eye and layers of the cornea. (Taken from Cleveland 
Clinic. https://my.clevelandclinic.org/health/treatments/17714-cornea-transplant) 
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2.0 Non-infectious Keratitis 
Non-infectious keratitis has a variety of potential causes, separate from infection from a 
pathogen. A common cause is ocular injury, be it via fingernail scratching, contact lenses, or 
another foreign object. Various disorders can also cause a loss of corneal sensitivity, which leads 
to a decrease in protective function like blinking, ultimately leading to keratitis. Similarly, in cases 
of systemic conditions like rheumatoid arthritis (RA) that result in severe dry eye, a lack of tear 
film that washes the cornea can lead to keratitis (Itty, Pulido et al. 2008). Exposure to intense UV 
light can also cause damage to the cornea, a condition known as photokeratitis, which can be 
caused by reflection of sunlight without proper eye protection. These causes of non-infectious 
keratitis are important risk factors for infectious keratitis if microbes are able to infiltrate the 
corneal epithelium, either by direct entry via injury, prolonged exposure from contaminated 
contacts, or epithelial susceptibility from an autoimmune disease (Voss, Nguyen et al. 2021).  
Current treatment options for non-infectious keratitis depend on the respective cause, but 
general treatment consists of anti-inflammatory treatments and lubrication (Voss, Nguyen et al. 
2021). Topical corticosteroids, in combination with artificial tears, are usually sufficient to treat 
mild cases of non-infectious keratitis due to foreign injury/irritation. If an individual is 
unresponsive to this initial treatment, steroid-sparing agents like 2% cyclosporine A or 0.02% 
tacrolimus have be utilized to safely resolve symptoms (Shoughy and Tabbara 2020). For systemic 
causes like RA, immunosuppressants such as methotrexate are used (Singh, Gupta et al. 2021). In 
more severe cases, systemic suppression or amniotic membrane grafting may be necessary. For 
neurotrophic keratitis, a specific type of non-infectious keratitis caused by damage to trigeminal 
innervation of the cornea, Cenergermin was recently approved by the FDA as a treatment option 
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(Deeks and Lamb 2020). This drug is an ophthalmic solution containing 20 ug/mL of recombinant 
human nerve growth factor. It is the first approved drug for treatment for this condition. When 
administered topically to patients six times a day, for eight weeks, corneal healing was 
significantly improved; however, it did not show significant improvement in corneal sensitivity or 
visual acuity (Deeks and Lamb 2020). This, combined with frequent administration, are current 
challenges with Cenergermin, but is a possible alternative to surgical treatment options that involve 
corneal gluing using cyanoacrulate-based adhesive, corneal transplant, or keratoplasty (Koganti, 
Yadavalli et al. 2021).  
With all causes of non-infectious keratitis, novel drug delivery methods are being used to 
provide sustained release of the therapeutic agent. These methods, such as use of  nanocarriers or 
drug-eluting ocular inserts, are also being investigated to treat infectious keratitis. Since emphasis 
is being put on their application for the latter type of keratitis, they will be discussed later in the 
review.  
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3.0 Infectious Keratitis 
Infectious, or microbial, keratitis is the predominant form of keratitis. In 2010, 76.5% of 
keratitis clinic visits in the US resulted in an antimicrobial prescription; it is estimated that 71,000 
cases of severe infectious keratitis occur each year (Collier, Gronostaj et al. 2014). Two cross-
sectional studies in 2014 estimated the prevalence of infectious keratitis in China to be, on average, 
0.170%. This amount was further categorized by viral, bacterial, and fungal causes, with an 
average prevalence of 0.0875%, 0.0715%, and 0.011%, respectively (Koganti, Yadavalli et al. 
2021). Quick and effective treatment of infectious keratitis is critical in stopping the progression 
of the infection. Many first-line treatments target inflammation, but do not necessarily take care of 
the infection; novel treatments and delivery methods are being researched to directly target the 
respective infection and reduce the burden of administration. However, many of these novel 
treatments are in early stages of research. As a result, clinical study is limited, and a majority of 
development is currently being performed in animal models. 
The most common animal models used to study microbial keratitis are mice and rabbits. 
Advantages of using mouse models are cost, convenience, and experimental consistency. Mice can 
also be genetically modified to lack certain aspects of a necessary immune response, such as 
cytokines and toll-like receptors, which increases susceptibility to infection. However, the main 
disadvantage of using mice is eye size. Rabbit eyes are larger and more similar to humans, which 
facilitates ocular investigation. The typical rabbit model used is the New Zealand White rabbit 
(NZW). For both mice and rabbits, bacteria and virulence factors can be injected into the cornea 
to produce infection, or topical inoculation can be utilized following corneal wounding.(Marquart 
2011) These different types of infection are used to study pathogen or host factors as it pertains to 
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keratitis; the former simulates a direct microbial infection, whereas the latter simulates non-
infectious keratitis that evolves through opportunistic infection, a pathology commonly seen in 
human patients. 
3.1 Viral Keratitis 
Herpes simplex virus type 1 (HSV-1) is the dominant cause of viral keratitis worldwide. 
The virus infects roughly two-thirds of the global population, with about 1.5 million individuals 
developing herpes simplex keratitis (HSK) every year (Koganti, Yadavalli et al. 2021). HSK is 
also a persistent disease, with 40% of infected individuals experiencing more than one relapse 
during their lifetime (Koganti, Yadavalli et al. 2021). Therefore, it is important to develop effective 
treatment methods that not only control symptoms of the disease to prevent ocular morbidity but 
prevent relapse as well.  
HSK treatment typically begins with standard medications, such as antiviral or 
glucocorticoid treatments. Trifluridine and acyclovir are the two most common antiviral studied 
in randomized controlled trials and prescribed for treatment of HSK, with the American Academy 
of Ophthalmology HSK guidelines and Herpetic Eye Disease Study recommending topical 
administration of these drugs as a first-line defense (Pandey, Choudhury et al. 2020). Trifluridine 
was the first FDA-approved drug for HSK treatment as a topical 1% ophthalmic solution that could 
be used every two hours (Koganti, Yadavalli et al. 2021). Trifluridine is a pyrimidine nucleoside 
that acts non-selectively to inhibit DNA synthesis both in infected and non-infected cells. As a 
result of this mechanism, however, prolonged use has been met with complications; ocular 
irritation, local toxicity, and inflammation have been observed after three weeks of daily use 
 8 
(Pandey, Choudhury et al. 2020). Trifluridine has thus fallen out of favor as a preferred treatment 
when compared to other antiviral options, but still remains effective for short-term use.  
Similar to trifluridine, acyclovir (ACV) is a purine nucleoside but with higher viral 
selectivity, leading to reduced prevalence of ocular side effects and toxicity (Pandey, Choudhury 
et al. 2020). ACV is well tolerated both orally and topically. Topical administration of acyclovir 
can be given up to five times per day and is formulated as a 3% ointment due to ACV’s high 
lipophilicity. However, ACV ointment administration results in lower bioavailability of ACV due 
to rapid nasolacrimal clearance, as well as blurred vision and difficulty during administration, 
leading to poor patient compliance (Pandey, Choudhury et al. 2020). As a result, ACV is preferred 
to be administered orally three-to-five times a day as 400-800mg tablets, in order to treat an active 
infection. Long-term prophylactic ACV therapy has also been shown to be effective in clinical 
trials but comes with the risk of systemic toxicity and inducing drug resistance, thereby reducing 
therapeutic efficacy (Koganti, Yadavalli et al. 2021). Antiviral-resistant strains of HSV in 
immunocompromised individuals are a particularly significant challenge. 
Other analogs of ACV, such as ganciclovir (GCV), cidofovir, and valacyclovir, have been 
studied as possible treatments for HSK. Topical GCV administration was studied on New Zealand 
White rabbits; a modified form of GCV, divaline-GCV (VVGCV), was found to have improved 
transcorneal permeability, and a 1% formulation of this GCV prodrug had greater efficacy when 
compared to 1% trifluridine (Majumdar, Nashed et al. 2005). Cidofovir has been found to be more 
effective than GCV when given intravenously for the first two weeks following infection, but must 
be administered intravenously or topically due to oral toxicity (Koganti, Yadavalli et al. 2021). 
Topical cidofovir administration was also found to be significantly more effective in treating HSK 
rabbit models than topical trifluridine and ACV (Romanowski, Bartels et al. 1999). 
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Glucocorticoid drops such as 0.1% prednisolone, 0.1% dexamethasone, and 0.5% 
loteprednol are often used in antiviral therapy to increase effectiveness of treatment (Guess, Stone 
et al. 2007). They have shown to be effective in reducing optical symptoms and inflammation that 
accompany HSK, but do not target the viral infection directly, so must be combined with antiviral 
agents discussed above (Koganti, Yadavalli et al. 2021). Furthermore, these treatments also come 
with some of the challenges as typical topical delivery, such as low bioavailability and blurred 
vision following administration. Because of these challenges, there is a need for novel drug 
delivery methods in treating HSK. 
A recent ocular insert that delivers G2-C, a cysteine-modified G2 peptide that blocks HSV-
1 entry into cells, has shown efficacy in treating HSK in vivo. This drug-loaded contact lens 
provides a more stable form of the G2 peptide for delivery and was capable of extended release 
(Jaishankar, Buhrman et al. 2016). Cationic peptides like G2 and G1 have repeatedly demonstrated 
efficacy in in vitro, ex vivo, and in vivo models (Pandey, Choudhury et al. 2020, Koganti, Yadavalli 
et al. 2021), but come with their own delivery challenges. Efficacy of these drugs are reduced if 
applied the day after infection, and the physiochemical properties of peptides make delivery 
difficult and time-consuming to formulate.  
Apart from optical inserts, various novel drug delivery systems are being researched to 
improve delivery of standard treatments, specifically ACV and GCV. One promising approach is 
the delivery of in situ gel formulations. These formulations exist as solutions before administration 
and undergo gelation when in presence of ocular environmental conditions like temperature, pH, 
and ionic strength. In situ gel systems exhibit a significant improvement in corneal drug contact 
due to prolonged release; this extended rate of release can be approximately five times slower than 
conventional topical drug administration (Pandey, Choudhury et al. 2020). Extended release time 
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equates to greater local bioavailability, improving the therapeutic effect of the drug. This sustained 
release is also found in nanoparticle formulations that are incorporated in an in situ gel formation. 
A relevant clinical study performed by Sirion Therapeutics, Inc. resulted in FDA approval in 2009 
of an in situ ophthalmic gel named Zirgan, which contains 0.15% GCV. In addition to the antiviral 
drug, carbomer 974P, water, sodium hydroxide, mannitol, and benzalkonium chloride are included 
in the formulation. This product is proven to significantly improve clinical effectiveness for 
patients with HSK with minimal side effects (Kaufman and Haw 2012). 
Various lipid-based nanocarriers are also being investigated for delivery of standard HSK 
treatments. Liposomes have a greater ability to interact with the corneal epithelium, and when 
combined with their small size, show improved ocular drug penetration and bioavailability; this 
especially beneficial when delivering poorly permeable antiviral drugs like ACV and GCV. Solid 
lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are similar to liposomes, but 
are more stable, less toxic, and able to be manufactured at a lower cost. These novel delivery 
methods have been shown to provide sustained release of antivirals, with NLCs exhibiting quicker 
drug release and more extensive corneal permeation when compared to SLNs, but both provide 
greater drug uptake by corneal epithelia cells than conventional suspensions (Pandey, Choudhury 
et al. 2020). 
Current investigation regarding alternatives to nucleoside analog therapy consist primarily 
of CRISPR/Cas9 technology applications. CRISPR/Cas9 has been used to successfully target 
herpes simplex viruses in multiple in vitro studies by manipulating viral miRNA, which can reduce 
the recurrence of keratitis post-infection (Koganti, Yadavalli et al. 2021). While this therapy is 
promising, there is a lack of in vivo study regarding safety and efficacy.   
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3.2 Bacterial Keratitis 
Bacterial keratitis is most commonly caused by Staphylococcus aureus, Streptococcus 
pneumoniae, and Pseudomonas aeruginosa. The primary risk factor for this type of infectious 
keratitis is prolonged use of contact lens; the risk of bacterial keratitis increases 9-15 fold if an 
individual sleeps with contacts overnight (Al-Mujaini, Al-Kharusi et al. 2009). Extended contact 
lens use, especially with those meant to be replaced daily, induces hypoxia, thereby increasing 
corneal temperature and decreasing tear flow over the corneal surface. The tear film serves a 
protective function for the cornea, so impaired tear production prevents the elimination of 
infectious microbes that come into contact with the corneal surface.  
Conventional therapy for bacterial keratitis consists of hourly administration of broad 
spectrum antibiotics (fluoroquinolones). These topical antibiotics are used as an initial treatment 
while culture results are being analyzed. Some FDA-approved quinolone antibiotics for treatment 
of BK are ciprofloxacin 0.3%, ofloxacin 0.3%, and levofloxacin 1.5% (Egrilmez and Yildirim-
Theveny 2020). After culture reports are available and response to initial treatment is evaluated, 
targeted treatment can be administered to the specific strain of bacteria present. For instance, 
moxifloxacin and gatifloxacin show higher potency against Gram-positive bacteria as opposed to 
Gram-negative organisms; if gram-negative organisms are found, ciprofloxacin may prove more 
effective (Lee, Somerville et al. 2021). In the case of fluoroquinolone-resistance bacteria, like 
MRSA, where an individual does not respond to initial antibiotic treatment, more potent antibiotics 
like vancomycin are effective in topical concentrations of 10-50 mg/mL (Egrilmez and Yildirim-
Theveny 2020). If targeted treatment is successfully given, clinical trials have shown that 
monotherapy with fluoroquinolones can be as effective as combination therapy with fortified 
antibiotic eye drops but with less toxicity (Al-Mujaini, Al-Kharusi et al. 2009, Wong, Gangwani 
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et al. 2012). Although antibiotic eyedrops are a common first-line treatment, frequent 
administration is inconvenient and tedious for the patient, causing an overall reduction in 
compliance. As a result, novel drug delivery methods are needed to increase compliance and 
therefore efficacy of treatment.  
Many of the novel drug delivery methods being studied to treat viral keratitis are also being 
studied for bacterial keratitis. Contact lenses have been developed to release antimicrobial drugs 
and drug-containing liposomes onto the cornea, such as ciprofloxacin, with demonstrated efficacy 
in ex vivo rabbit models (Hui, Willcox et al. 2014) A moxifloxacin (MF) and dexamethasone 
(DM)-eluting contact lens is another one of these non-standard treatment methods currently being 
investigated (Gade, Nirmal et al. 2020). In this study, a polymeric contact lens using chitosan, 
glycerol, and PEG was developed along with MF and DM. Drug-loaded contact lenses were tested 
with a combination of drugs as well as individually, and all three lenses were compared to 
treatment with individual drug solutions. The combined drug-loaded contact lens achieved the 
required therapeutic concentration of MF and showed significantly greater corneal drug 
distribution when compared to the individual drug solutions given topically to rabbits and humans. 
Furthermore, the contact lens showed mucoadhesion as well as both in vitro and in vivo 
antimicrobial activity (Gade, Nirmal et al. 2020). Moxifloxacin-loaded nanoparticles have also 
shown increased corneal penetration compared to solution, and in situ gel formulations can be 
combined with these nanoparticles for improved therapeutic effect (Lee, Somerville et al. 2021).  
Apart from lenses offering sustained release of drugs, antimicrobial compounds have been 
incorporated into the lens itself; AGMNA, a metal organic framework featuring silver (a natural 
antimicrobial agent), has been developed both for inclusion into the contact lens structure and as 
a lens disinfecting agent, with high effectiveness and minimal toxicity (Rossos, Banti et al. 2020). 
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Furthermore, a combined in vitro and in vivo study showed that microemulsions demonstrate 
improvement in delivering antibiotic drugs to the epithelium in rabbit keratitis (Lee, Somerville et 
al. 2021). Combining conventional fluoroquinolone therapy with microemulsion delivery systems 
may improve the efficacy and tolerability of these drugs. Various novel antimicrobial peptides 
have been studied that are effective against S. aureus, which may prove beneficial in treating cases 
of BK caused by antibiotic-drug resistant bacteria. Some of these peptides include LyeTxI-b, D-
Arg4-Leu10-Teixobactin, and RP442/3/4, which work by altering cellular interactions with the 
bacterial membrane. However, these peptides come with concerns over toxicity and stability, and 
thus need to be investigated further (Lee, Somerville et al. 2021). 
Cysteine protease inhibitors have been implied as a potential therapeutic agent for treating 
BK; upon infection, bacterial pathogens secrete cysteine proteases which degrade proteins in the 
corneal environment. Surfactant protein D (SP-D), a removal agent typically present in the tear 
film, aggregates bacteria and facilitates pathogenic clearance. SP-D knockout mice were 
genetically modified to have increased susceptibility to bacterial keratitis, partly due to increased 
vulnerability to pathogenic secretion of these proteases. Treating SP-D KO mice with a cysteine 
protease inhibitor recovered the antimicrobial effects of (SP-D) (Zhang, Abdel-Razek et al. 2015). 
Further investigation is needed to assess whether these inhibitors can be effective therapeutic 
agents. 
3.3 Fungal Keratitis 
Fungal keratitis (FK) is primarily caused by filamentous (Fusarium, Aspergillus) and 
yeast-like (Candida) fungi. The major risk factor for developing fungal keratitis is ocular trauma 
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with vegetative matter, typically within rural farming areas of developing countries. In developed 
countries like the US, contact use is the primary risk factor (Ng, Fraunfelder et al. 2013). 
Treatment of fungal keratitis involves oral/topical antifungal medications specific to the 
type of fungi responsible for the condition. Natamycin is the preferred first-line treatment for 
filamentous fungi and was the first approved antifungal agent for FK. It is administered hourly as 
5% eyedrops; however, natamycin has poor penetration into the cornea, so is typically combined 
with 1% topical voriconazole if no significant therapeutic benefit is observed. Voriconazole 
features a wider therapeutic window along with broad antifungal activity, but has been reported to 
have minimal effect when given alone, an effect that may not be significantly different than 
placebo (Singh, Gupta et al. 2021). Clinical study has shown a similar therapeutic benefit to 
natamycin when the two drugs are given together; since natamycin is commercially available, it is 
usually preferred as initial treatment (Ansari, Miller et al. 2013). However, because natamycin has 
poor penetration and is ineffective against Candida fungi, it is limited to superficial FK.  
In the case of Candida infection, Amphotericin B can be administered topically (0.15%) 
or intracamerally with significant benefit. Although, it is less effective against Fusarium species, 
has similar penetration to natamycin, and can be toxic if administered intravenously in high doses 
(Ansari, Miller et al. 2013). Fluconazole is another option for elimination of Candida in cases 
where greater intraocular penetration is required. It can be given topically, orally, or intravenously 
with minimal side effects. Topical fluconazole has been shown to effectively treat FK in 
individuals who do not respond to Amphotericin B and can be given as an adjunct to natamycin or 
Amphotericin B, depending on the species of fungi (Ng, Fraunfelder et al. 2013). This broadens 
antifungal effects and improves the chance of a successful treatment. Cyclosporine has also been 
implicated as a possible management option for FK; it was shown to have antifungal and anti-
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immune properties in patients with FK undergoing corneal transplant, but sample size was limited 
(Ansari, Miller et al. 2013). 
3.4 Amoebic Keratitis 
Amoebic keratitis (AK) is a more uncommon type of infectious keratitis caused primarily 
by the genus of amoeba known as Acanthamoeba. Given this distinct causal pathogen, the primary 
risk factor is exposure to soil or contaminated water while wearing contact lenses; this risk can be 
compounded by ocular damage. The incidence of AK in the United States is estimated to be two 
new annual cases per one-million contact lens wearers, although a recent investigation in Iowa 
reported a tripling of AK cases during 2010-2017 (Scruggs, Brittni et al. 2019). This study was 
performed in Iowa but raises the possibility of similar surges in AK cases in other states. 
The clinical pathology of AK is similar to that of other forms of keratitis, including intense 
pain, ocular oedema, epithelial defect, and eventual loss of vision (Lorenzo-Morales, Khan et al. 
2015). Ring infiltrates are commonly seen in amoebic keratitis, which can progress to create a 
disease state indistinguishable from bacterial and fungal keratitis (Singh, Gupta et al. 2021). 
Because AK can present itself similarly to more common types of keratitis, misdiagnosis is a main 
issue. The other significant issue with treatment is the pathogen itself; Acanthamoeba has two 
forms, a metabolically-active trophozoite and a dormant, resistive cyst stage (Lorenzo-Morales, 
Khan et al. 2015). While the former is much more effectively handled with treatment, the latter is 
more resistant; successful treatment is determined by elimination of both forms of Acanthamoeba. 
The first line treatment for AK are biguanides such as 0.02% polyhexamethylene biguanide 
(PHMB) and 0.02% chlorhexidine. They have proven to be effective for treating the amoebic 
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infection and are active against both trophozoites and cysts when combined (Lorenzo-Morales, 
Khan et al. 2015). These drugs are administered topically every hour for the first few days post-
diagnosis, and then tapered off over the course of several weeks depending on clinical response. 
Although these drugs are effective, PHMB in particular can be damaging to corneal cells, and 
epithelia toxicity can develop with frequent/extended use of the drug. The increased inflammation 
and side effects that come with this condition may require the use of topical steroids, but there is 
evidence that steroid use in the presence of Acanthamoeba may actually increase protozoal 
abundance (Lorenzo-Morales, Khan et al. 2015). If biguanides are not initially successful, possibly 
due to resistant Acanthamoeba, PHMB and chlorhexidine may be combined with antimicrobial 
agents like pentamidine or levofloxacin to speed up treatment and reduce the risk of developmental 
toxicity (Singh, Gupta et al. 2021). If all of these pharmaceutical treatments do not work, corneal 
transplant is usually performed to prevent progression of the condition. Because of these 
challenges, novel treatments for AK are necessary, but literature on this topic is minimal. 
Phosphocholines have been shown to have antineoplastic activity in vitro and in vivo. A 
particular drug of this class, miltefosine, has been shown to be effective against Acanthamoeba. 
Miltefosine was combined with polyhexamethylene biguanide for enhanced treatment of AK in 
rats, healing approximately 86% of infected eyes (Polat, Walochnik et al. 2014). Recently, a 
“pharmaceutical phylogeny” started for Acanthamoeba to identify new therapeutic sites that can 
be targeted by novel or conventional drugs in order to improve efficacy of treatment (Lorenzo-
Morales, Khan et al. 2015). Although the current number of novel drugs and delivery methods for 
treating AK are few, it is possible that efficacy of current treatment options like biguanides may 
be enhanced in the future through previously-mentioned delivery methods being studied for other, 
more common types of infectious keratitis. 
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3.5 Non-Pharmaceutical Treatment 
Despite the development of many promising delivery methods for the treatment of 
infectious keratitis, expense, delivery complications, and lack of established safety/efficacy data 
limit clinical use. A novel, non-pharmaceutical treatment method under clinical investigation for 
infectious keratitis is corneal crosslinking (CXL). CXL has been utilized, albeit in small numbers, 
to treat infectious keratitis when patient response to pharmaceutical drugs is nominal (Lee, 
Somerville et al. 2021). CXL takes advantage of free radical generation from the combination of 
UV light and riboflavin to damage microbial DNA, and produces corneal resistance to proteolytic 
enzymes generated by pathogenic microbes; this technique has demonstrated effectiveness both in 
vitro and in vivo in treatment of bacterial keratitis, but can be combined with antibiotic therapy to 
further improve therapeutic effect (Egrilmez and Yildirim-Theveny 2020). In cases of fungal 
keratitis, CXL has been shown to have significant therapeutic benefit, healing corneal epithelium 
and improving visual acuity within two weeks post-treatment (Ng, Fraunfelder et al. 2013). CXL 
has also significantly improved AK within 24 hours in four individuals, further resolving all 
symptoms/epithelial defects within three months; no Acanthamoeba was detected in corneal tissue 
following this period of time. Concern has arisen over exposing the cornea to UV light, which can 
possibly result in corneal melt, a severe symptom of infectious keratitis itself. To negate this, a 
topical CXL approach has been developed that utilizes sodium hydroxymethylglycinate as the 
cross-linking agent instead of UVA/riboflavin in vitro, but further clinical investigation is required 
if this is to become a viable alternative (Lee, Somerville et al. 2021).  
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4.0 Conclusion 
Despite recent advancements in the field, treatment of keratitis remains a difficult task. 
Corticosteroid eye drops are the typical first-line treatment for most cases of keratitis, including 
non-infectious keratitis, where cyclosporine and tacrolimus can be used if the patient is 
unresponsive to treatment. Cenergermin, a topical solution consisting of recombinant human nerve 
growth factor, was recently approved by the FDA. Although these topical treatments are welcome 
alternatives to surgical intervention, the frequent administration and low bioavailability 
necessitates novel delivery methods.  
Topical trifluridine and acyclovir are common first-line treatments for viral keratitis caused 
by HSV-1 infection, as well as other analogs of ACV. Glucocorticoid drops are used in 
combination with these therapeutic agents to increase effectiveness of treatment. Ocular inserts 
consisting of antimicrobial drugs and peptides have been developed, both for treatment of viral 
and bacterial keratitis. Moxifloxacin is one of the fluoroquinolones used to treat bacterial keratitis 
and has been included as part of a nanoparticle carrier to increase corneal penetration. In situ gel 
formulations are being developed to prolong the release of drugs onto the cornea, as well as the 
use of lipid carriers. Topical antifungal agents are used in treatment of fungal keratitis, including 
Natamycin, Voriconazole, and Amphotericin B, depending on the type of fungi. Cyclosporine is 
currently being investigated as a novel treatment method for this specific kind of keratitis. Lastly, 
biguanides are conventionally used to treat Acanthamoeba keratitis; phosphocholines such as 
miltefosine are being investigated as novel treatment options. For most types of keratitis, corneal 
crosslinking has been used successfully, but total case numbers are low. Overall, novel treatments 
for ocular conditions, especially keratitis, remain an important topic in the field of drug delivery.   
 19 
Bibliography 
Al-Mujaini, A., N. Al-Kharusi, A. Thakral and U. K. Wali (2009). "Bacterial keratitis: perspective 
on epidemiology, clinico-pathogenesis, diagnosis and treatment." Sultan Qaboos Univ 
Med J 9(2): 184-195. 
Ansari, Z., D. Miller and A. Galor (2013). "Current Thoughts in Fungal Keratitis: Diagnosis and 
Treatment." Current Fungal Infection Reports 7(3): 209-218. 
Cleveland Clinic. (2018). "Cornea Transplant." Retrieved from 
https://my.clevelandclinic.org/health/treatments/17714-cornea-transplant. 
Collier, S. A., M. P. Gronostaj, A. K. MacGurn, J. R. Cope, K. L. Awsumb, J. S. Yoder and M. J. 
Beach (2014). "Estimated burden of keratitis--United States, 2010." MMWR Morb Mortal 
Wkly Rep 63(45): 1027-1030. 
Deeks, E. D. and Y. N. Lamb (2020). "Cenegermin: A Review in Neurotrophic Keratitis." Drugs 
80(5): 489-494. 
Egrilmez, S. and Ş. Yildirim-Theveny (2020). "Treatment-Resistant Bacterial Keratitis: 
Challenges and Solutions." Clin Ophthalmol 14: 287-297. 
Gade, S. K., J. Nirmal, P. Garg and V. V. K. Venuganti (2020). "Corneal delivery of moxifloxacin 
and dexamethasone combination using drug-eluting mucoadhesive contact lens to treat 
ocular infections." Int J Pharm 591: 120023. 
Guess, S., D. U. Stone and J. Chodosh (2007). "Evidence-based treatment of herpes simplex virus 
keratitis: a systematic review." Ocul Surf 5(3): 240-250. 
Hui, A., M. Willcox and L. Jones (2014). "In vitro and in vivo evaluation of novel ciprofloxacin-
releasing silicone hydrogel contact lenses." Invest Ophthalmol Vis Sci 55(8): 4896-4904. 
Itty, S., J. S. Pulido, S. J. Bakri, K. H. Baratz, E. L. Matteson and D. O. Hodge (2008). "Anti-cyclic 
citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid 
arthritis." Trans Am Ophthalmol Soc 106: 75-81; discussion 81-73. 
Jaishankar, D., J. S. Buhrman, T. Valyi-Nagy, R. A. Gemeinhart and D. Shukla (2016). "Extended 
Release of an Anti-Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal 
Herpes Simplex Virus-1 Infection." Invest Ophthalmol Vis Sci 57(1): 169-180. 
Kaufman, H. E. and W. H. Haw (2012). "Ganciclovir ophthalmic gel 0.15%: safety and efficacy 
of a new treatment for herpes simplex keratitis." Curr Eye Res 37(7): 654-660. 
Koganti, R., T. Yadavalli, R. A. Naqvi, D. Shukla and A. R. Naqvi (2021). "Pathobiology and 
treatment of viral keratitis." Exp Eye Res 205: 108483. 
 20 
Lee, J. W., T. Somerville, S. B. Kaye and V. Romano (2021). "Staphylococcus aureus Keratitis: 
Incidence, Pathophysiology, Risk Factors and Novel Strategies for Treatment." J Clin Med 
10(4). 
Lorenzo-Morales, J., N. A. Khan and J. Walochnik (2015). "An update on Acanthamoeba keratitis: 
diagnosis, pathogenesis and treatment." Parasite (Paris, France) 22: 10-10. 
Majumdar, S., Y. E. Nashed, K. Patel, R. Jain, M. Itahashi, D. M. Neumann, J. M. Hill and A. K. 
Mitra (2005). "Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced 
corneal epithelial and stromal keratitis: in vitro and in vivo evaluations." J Ocul Pharmacol 
Ther 21(6): 463-474. 
Marquart, M. E. (2011). "Animal models of bacterial keratitis." J Biomed Biotechnol 2011: 
680642. 
Ng, J. K., F. W. Fraunfelder and K. L. Winthrop (2013). "Review and Update on the Epidemiology, 
Clinical Presentation, Diagnosis, and Treatment of Fungal Keratitis." Current Fungal 
Infection Reports 7(4): 293-300. 
Pandey, M., H. Choudhury, A. Abdul-Aziz, S. K. Bhattamisra, B. Gorain, J. S. T. Su, C. L. Tan, 
W. Y. Chin and K. Y. Yip (2020). "Advancement on Sustained Antiviral Ocular Drug 
Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation." 
Pharmaceutics 13(1). 
Polat, Z. A., J. Walochnik, A. Obwaller, A. Vural, A. Dursun and M. K. Arici (2014). "Miltefosine 
and polyhexamethylene biguanide: a new drug combination for the treatment of 
Acanthamoeba keratitis." Clin Exp Ophthalmol 42(2): 151-158. 
Romanowski, E. G., S. P. Bartels and Y. J. Gordon (1999). "Comparative antiviral efficacies of 
cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model." Invest 
Ophthalmol Vis Sci 40(2): 378-384. 
Rossos, A. K., C. N. Banti, A. G. Kalampounias, C. Papachristodoulou, K. Kordatos, P. 
Zoumpoulakis, T. Mavromoustakos, N. Kourkoumelis and S. K. Hadjikakou (2020). 
"pHEMA@AGMNA-1: A novel material for the development of antibacterial contact 
lens." Mater Sci Eng C Mater Biol Appl 111: 110770. 
Scruggs, B. A., T. S. Quist, J. L. Salinas and M. A. Greiner (2019). "Notes from the Field: 
Acanthamoeba Keratitis Cases - Iowa, 2002-2017." MMWR. Morbidity and mortality 
weekly report 68(19): 448-449. 
Shoughy, S. S. and K. F. Tabbara (2020). "Topical Tacrolimus in Thygeson Superficial Punctate 
Keratitis." Cornea 39(6): 742-744. 
Singh, P., A. Gupta and K. Tripathy (2021). Keratitis. StatPearls. Treasure Island (FL), StatPearls 
Publishing Copyright © 2021, StatPearls Publishing LLC. 
 21 
Voss, K., A. Nguyen and M. Heur (2021). "Non-infectious and non-hereditary diseases of the 
corneal epithelium." Experimental Eye Research 202: 108316. 
Wong, R. L., R. A. Gangwani, L. W. Yu and J. S. Lai (2012). "New treatments for bacterial 
keratitis." J Ophthalmol 2012: 831502. 
Zhang, Z., O. Abdel-Razek, S. Hawgood and G. Wang (2015). "Protective Role of Surfactant 
Protein D in Ocular Staphylococcus aureus Infection." PLoS One 10(9): e0138597. 
 
